Breaking News Instant updates and real-time market news.

ABMD

Abiomed

$119.79

-0.94 (-0.78%)

, MDT

Medtronic

$81.54

-0.32 (-0.39%)

07:47
03/07/17
03/07
07:47
03/07/17
07:47

FDA Pediatric Advisory Committee to hold a meeting

The Committee discusses pediatric-focused safety reviews, as mandated by The FDA Safety and Innovation Act (FDASIA), for Novo Nordisk's NOVOEIGHT (Antihemophilic Factor ) and Shire's RIXUBIS Coagulation Factor IX (Recombinant). Additionally, The Committee discusses the safety of and the ongoing propriety of the humanitarian device exemption for Vericel's EPICEL (cultured epidermal autografts) (HDE), Abiomed's IMPELLA RP SYSTEM (HDE), Kaneka's LIPOSORBER LA-15 SYSTEM (HDE) and Medtronic's MEDTRONIC ACTIVA DYSTONIA THERAPY (HDE). The meeting is being held in Silver Spring MD on March 7 at 8:30 am. Webcast Link

ABMD

Abiomed

$119.79

-0.94 (-0.78%)

MDT

Medtronic

$81.54

-0.32 (-0.39%)

NVO

Novo Nordisk

$33.92

-0.76 (-2.19%)

SHPG

Shire

$184.48

-1.82 (-0.98%)

VCEL

Vericel

$2.85

-0.05 (-1.72%)

  • 07

    Mar

  • 07

    Mar

  • 10

    Mar

  • 14

    Mar

  • 14

    Mar

  • 17

    Mar

  • 21

    Mar

  • 23

    Mar

  • 24

    Mar

  • 01

    Apr

  • 26

    Jun

ABMD Abiomed
$119.79

-0.94 (-0.78%)

12/07/16
12/07/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Micron (MU) initiated with a Buy at Citi. 2. Owens Corning (OC) initiated with a Buy at Seaport Global. 3. Abiomed (ABMD) initiated with a Buy at Guggenheim. 4. ZELTIQ (ZLTQ) initiated with a Buy at Aegis. 5. Navient (NAVI) initiated with a Hold at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/07/16
GUGG
12/07/16
INITIATION
Target $150
GUGG
Buy
Abiomed initiated with a Buy at Guggenheim
Guggenheim analyst Christopher Pasquale initiated Abiomed with a Buy and a $150 price target.
12/06/16
GUGG
12/06/16
INITIATION
GUGG
Buy
Abiomed initiated with a Buy at Guggenheim
11/18/16
LEER
11/18/16
NO CHANGE
Target $140
LEER
Outperform
Abiomed remains on 'hyper-growth trajectory,' says Leerink
After hosting investor meetings with the company's CEO Mike Minogue, CFO Mike Tomsicek, and Director of IR Ingrid Goldberg, Leerink analyst Danielle Antalffy remains confident that Abiomed's fundamentals are intact, and the company remains on a "hyper-growth trajectory" with significant positive operating leverage. The analyst remains confident in a sustainable long-term "strong" double-digit growth trajectory built on a market-leading product, a large and still-expanding salesforce, and a "strong" foundation of clinical evidence. She reiterates an Outperform rating and $140 price target on the shares.
MDT Medtronic
$81.54

-0.32 (-0.39%)

02/14/17
WELS
02/14/17
NO CHANGE
WELS
Medtronic data likely to be positive, says Wells Fargo
Wells Fargo predicts that data on Medtronic's (MDT) CoreValve/Evolut R, due to be presented on March 17, will show that the device "is superior to surgical aortic valve replacement in intermediate risk patients." If the results come in as expected, the device should be approved in the U.S. by early fall, according to the firm. Wells Fargo adds that the data should also be a positive for other TAVR stocks, including Edwards Lifesciences (EW) and Boston Scientific (BSX). Wells keeps Outperform ratings on all three stocks.
02/15/17
DBAB
02/15/17
NO CHANGE
Target $96
DBAB
Buy
Medtronic shares have more upside, says Deutsche Bank
Deutsche Bank analyst Kristen Stewart says the recent stock appreciation has not changed her bullish view on Medtronic. Ahead of the company's Q3 results on February 21, Stewart sees more upside in the stock. She keeps a Buy rating on Medtronic with a $96 price target.
02/22/17
NEED
02/22/17
NO CHANGE
Target $91
NEED
Buy
Medtronic price target raised to $91 from $84 at Needham
Needham analyst Mike Matson raised his price target for Medtronic to $91 from $84 after Q3 revenue and EPS beat consensus and the company maintained its 2017 guidance. The analyst believes the shares remain at a discount to peers and reiterates a Buy rating on the stock.
02/23/17
LEER
02/23/17
NO CHANGE
Target $85
LEER
Market Perform
Medtronic price target raised to $85 from $80 at Leerink
Leerink analyst Danielle Antalffy raised her price target for Medtronic to $85 from $80 after the company delivered what he believes was an "encouraging rebound" quarter after an unexpected Q2 miss. While the analyst remains cautious on the company's ability to manage through what could be meaningful top-line headwinds in Q4 and FY18 in order to deliver a targeted mid-single-digit sales growth, it does seem that the diversified business model gives it a cushion with which to offset underperforming business segments with stronger/faster growth elsewhere. He reiterates a Market Perform rating on the shares.
NVO Novo Nordisk
$33.92

-0.76 (-2.19%)

02/02/17
DBAB
02/02/17
NO CHANGE
DBAB
Novo Nordisk added to short-term buy list at Deutsche Bank
01/04/17
JPMS
01/04/17
DOWNGRADE
JPMS
Underweight
Novo Nordisk downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Richard Vosser downgraded Novo Nordisk yesterday to Underweight saying consensus expectations are not reflecting the potential for further pricing pressure in the U.S. The analyst has a DKR 225 price target for the shares.
01/03/17
JPMS
01/03/17
DOWNGRADE
JPMS
Underweight
Novo Nordisk downgraded to Underweight from Neutral at JPMorgan
12/15/16
HCWC
12/15/16
NO CHANGE
Target $13
HCWC
Buy
vTv Therapeutics Phase 2 diabetes data a 'big win,' says H.C. Wainwright
H.C. Wainwright analyst Corey Davis views vTv Therapeutics' (VTVT) data from its Phase 2 study of TTP273 in type-2 diabetes as "very positive" and a "big win." Efficacy is close to Novo Nordisk's (NVO) oral semaglutide, Davis tells investors in a research note. vTv is "highly likely" to succeed in finding a partner given the attractiveness of the diabetes market and the differentiated profile '273 has now created, the analyst contends. Davis keeps a Buy rating on the shares with a $13 price target.
SHPG Shire
$184.48

-1.82 (-0.98%)

12/02/16
SOCG
12/02/16
INITIATION
SOCG
Buy
Shire initiated with a Buy at Societe Generale
12/02/16
12/02/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Exxon Mobil (XOM) initiated at BMO Capital. 2. Pfizer (PFE) initiated with a Neutral at Guggenheim. 3. DuPont Fabros (DFT) initiated with a Neutral at Guggenheim. 4. Acadia (ACHC) resumed with a Buy at Jefferies. 5. Shire (SHPG) initiated with a Buy at Societe Generale. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/19/17
01/19/17
NO CHANGE

Shire's application for ADHD disorder candidate acknowledged by FDA
Shire announced that the FDA has acknowledged receipt of the Class 2 resubmission of a New Drug Application for SHP465, a long-acting, triple-bead, mixed amphetamine salts formulation. SHP465 is being evaluated as a potential once-daily treatment for Attention-Deficit/Hyperactivity Disorder. The FDA is expected to provide a decision on or around June 20. Shire resubmitted the NDA for SHP465 in response to the Approvable Letter from the FDA that requested additional clinical studies and classified the response as a Class 2 resubmission with a review goal of six months. Launch is planned for the second half of 2017.
12/06/16
UBSW
12/06/16
DOWNGRADE
UBSW
Neutral
Shire downgraded to Neutral from Buy at UBS
VCEL Vericel
$2.85

-0.05 (-1.72%)

03/10/16
LTCO
03/10/16
NO CHANGE
Target $8.45
LTCO
Buy
Vericel Phase IIb trial success a surprise, says Ladenburg
Ladenburg analyst Kevin DeGeeter said he and, in his view, most investors, had low expectations for Vericel's Phase IIb study of ixmyelocel-T in advanced heart failure patients due to ischemic dilated cardiomyopathy, or DCM. DeGeeter noted that he didn't have any value for DCM in his valuation and will reevaluate following the company's release of full data in early April. The analyst reiterates a Buy rating and $8.45 price target on Vericel shares, which are up 89% to $4.00 in afternoon trading.
12/22/16
PIPR
12/22/16
INITIATION
Target $6
PIPR
Overweight
Vericel initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff initiated Vericel with an Overweight rating and $6 price target, saying he sees the company's recently approved Matrix-induced Autologous Chondrocyte Implant to drive cartilage repair growth. Tenthoff predicts combined knee ACI sales growth of 23.3% to $44.5M in 2017 and then MACI growth of 21% to $54M in 2018.
03/11/16
NEED
03/11/16
UPGRADE
NEED
Buy
Vericel upgraded to Buy from Hold at Needham

TODAY'S FREE FLY STORIES

XENE

Xenon Pharmaceuticals

, AMGN

Amgen

$170.77

1.39 (0.82%)

14:29
11/17/17
11/17
14:29
11/17/17
14:29
Periodicals
Xenon higher as CNBC's Tirrell reports on nonaddictive pain medicines »

Six drug companies are…

XENE

Xenon Pharmaceuticals

AMGN

Amgen

$170.77

1.39 (0.82%)

RHHBY

Roche

$28.90

0.165 (0.57%)

BIIB

Biogen

$313.98

3.7 (1.19%)

RGEN

Repligen

$33.73

1.12 (3.43%)

VRTX

Vertex

$147.94

-0.72 (-0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 30

    Nov

  • 30

    Nov

  • 02

    Dec

  • 23

    Dec

  • 03

    Feb

  • 23

    Feb

  • 30

    Apr

  • 17

    May

  • 28

    May

RIO

Rio Tinto

$47.70

0.065 (0.14%)

14:25
11/17/17
11/17
14:25
11/17/17
14:25
Periodicals
Rio Tinto working with advisers on bid for stake in SQM, Bloomberg says »

Rio Tinto has lined up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIAB

Viacom

$23.69

-0.92 (-3.74%)

14:25
11/17/17
11/17
14:25
11/17/17
14:25
Options
Viacom call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:25
11/17/17
11/17
14:25
11/17/17
14:25
General news
Action Economics Survey results »

Action Economics Survey…

TWX

Time Warner

$88.79

0.7799 (0.89%)

, DIS

Disney

$103.63

0.03 (0.03%)

14:23
11/17/17
11/17
14:23
11/17/17
14:23
Periodicals
'Justice League' grosses roughly $16M in opening day in China, Forbes says »

Warner Bros. (TWX) latest…

TWX

Time Warner

$88.79

0.7799 (0.89%)

DIS

Disney

$103.63

0.03 (0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

14:17
11/17/17
11/17
14:17
11/17/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
11/17/17
11/17
14:16
11/17/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAAS

Pan American Silver

$14.77

-0.12 (-0.81%)

14:00
11/17/17
11/17
14:00
11/17/17
14:00
Conference/Events
Pan American Silver investor and analyst day »

Investor and Analyst Day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

TJX

TJX

$70.99

1.93 (2.79%)

14:00
11/17/17
11/17
14:00
11/17/17
14:00
Options
Notable options activity in TJX as shares see strength »

Notable options activity…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFSW

PFSweb

$6.80

0.21 (3.19%)

13:59
11/17/17
11/17
13:59
11/17/17
13:59
Hot Stocks
PFSweb rallies after Ancora discloses activist stake »

Ancora Advisors earlier…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RH

RH

$103.86

-0.95 (-0.91%)

13:52
11/17/17
11/17
13:52
11/17/17
13:52
Recommendations
RH analyst commentary  »

RH price target raised to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAIN

Hain Celestial

$38.49

1.76 (4.79%)

13:45
11/17/17
11/17
13:45
11/17/17
13:45
Options
Hain Celestial call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PEG

PSEG

$51.40

0.015 (0.03%)

13:36
11/17/17
11/17
13:36
11/17/17
13:36
Syndicate
Breaking Syndicate news story on PSEG »

PSEG files $129.1M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AWK

American Water

$89.05

-0.64 (-0.71%)

13:33
11/17/17
11/17
13:33
11/17/17
13:33
Hot Stocks
Indiana American Water acquires Georgetown Water System for about $6.4M »

Indiana American Water…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COT

Cott Corp.

$16.86

0.36 (2.18%)

13:30
11/17/17
11/17
13:30
11/17/17
13:30
Options
Cott Corp call buying continues »

Cott Corp call buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:30
11/17/17
11/17
13:30
11/17/17
13:30
General news
FX Action: USD-JPY »

FX Action: USD-JPY…

CC

Chemours

$52.23

0.705 (1.37%)

13:27
11/17/17
11/17
13:27
11/17/17
13:27
Periodicals
Chemours tells Bloomberg N.C. permit revocation 'unwarranted' »

The comment was issued by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Dec

13:25
11/17/17
11/17
13:25
11/17/17
13:25
General news
An exodus from U.S. high yield debt this week »

An exodus from U.S. high…

STBZ

State Bank Financial

$28.69

0.21 (0.74%)

13:25
11/17/17
11/17
13:25
11/17/17
13:25
Conference/Events
State Bank Financial participates in a conference call with SunTrust »

Suntrust Bank Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Nov

HIBB

Hibbett Sports

$14.85

0.8 (5.69%)

13:24
11/17/17
11/17
13:24
11/17/17
13:24
Recommendations
Hibbett Sports analyst commentary  »

Hibbett Sports price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Nov

FL

Foot Locker

$40.18

8.33 (26.15%)

13:23
11/17/17
11/17
13:23
11/17/17
13:23
Recommendations
Foot Locker analyst commentary  »

Foot Locker quarter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Nov

MS

Morgan Stanley

$48.67

0.065 (0.13%)

13:20
11/17/17
11/17
13:20
11/17/17
13:20
Options
Morgan Stanley calls lead puts 9:1 »

Morgan Stanley calls lead…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

13:17
11/17/17
11/17
13:17
11/17/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
11/17/17
11/17
13:16
11/17/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:15
11/17/17
11/17
13:15
11/17/17
13:15
General news
Oil Action: Baker Hughes »

Oil Action: Baker Hughes…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.